Tucatinib,Trastuzumab,Trastuzumab deruxtecan
seagen,astrazeneca,daiichi sankyo
 due to the findings as noted in the mypathway clinical trial, most of the ongoing #her2 trials exclude patients with #kras-mutation. since these are likely mechanisms of resistance to tki or monoclonal antibody. can use t-dxd. #wcgic2022 
Oncologist | Researcher | ColorectalCancer #CRCSM???????@MayoClinic @PittTweet Alum; ??#ctDNA #LiquidBiopsies??#PrecisionOncology ViewsMy Own. COI @ASCO #ASCO22